Abraxis Fails To Nix Naropin Suit Antitrust Claims
Abraxis BioScience Inc. was unable to toss antitrust cross-claims in its patent infringement case seeking to block a generic manufacturer from launching a copycat version of its injectable pain management drug...To view the full article, register now.
Already a subscriber? Click here to view full article